Results 281 to 290 of about 1,006,148 (403)

PRC2-Related Epigenetic Age Acceleration in Acute Myeloid Leukemia with DNMT3A and IDH2 Mutations. [PDF]

Adv Biol (Weinh)
Yan Z, Yuan L, Wang J, Gu S, Lei Y.
europepmc   +1 more source

Extracellular vesicle‐based vaccines and immunotherapeutics for treatment of cancer

Interdisciplinary Medicine, EarlyView.
This review highlights the innovative value of extracellular vesicles (EVs) as cancer vaccines and immunotherapy carriers. EVs have natural advantages such as low immunogenicity, high biocompatibility, stability, and precise targeting, enabling efficient delivery of tumor antigens (e.g., HER2, AFP) and immune stimulants (e.g., TLR ligands, cytokines ...
Lejia Tan, Haonan Xing, Fang Fang, Yuanyu Huang, Mei Lu   +4 more
wiley   +1 more source

Hypoxic conditions confer chemoresistance to crizotinib but not to imatinib in chronic myeloid leukemia cells. [PDF]

Hematol Transfus Cell Ther
Avinery L, Regev D, Khamaisi H, Gopas J, Mahajna J.   +4 more
europepmc   +1 more source

Most costly and prevalent reasons for hospitalization in children with medical complexity in Ontario, Canada

Journal of Hospital Medicine, EarlyView.
Abstract Background and Objectives Children with medical complexity (CMC) have chronic health conditions often associated with functional limitations. CMC comprise 1%–5% of the pediatric population. In Canada, their care accounts for one‐third of pediatric health spending.
Erin Hessey, Thaksha Thavam, Sanjay Mahant, Eyal Cohen, Jingqin Zhu, Francine Buchanan, Teresa To, Peter J. Gill, Ontario Pediatric Hospital Care Study Group (OPHCSG) and the Canadian Paediatric Inpatient Research Network (PIRN), Wenjia Chen, Ronald Cohn, Mairead Green, Matt Hall, Kate Langrish, Colin Macarthur, Myla Moretti, Patricia Parkin, Michelle Quinlan, Ann Bayliss, Ronik Kanani, Sean Murray, Catherine Pound, Mahmoud Sakran, Anupam Sehgal, Sepi Taheri, Gita Wahi   +25 more
wiley   +1 more source

Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia – Cancer and leukemia group B study 10107

, 2008
Meir Wetzler, Kathleen Donohue, Olatoyosi Odenike, Eric J. Feldman, David D. Hurd, Richard M. Stone, Peter Westerfelt, Clara D. Bloomfield, Richard A. Larson   +8 more
openalex   +1 more source

Artificial intelligence strategies for predicting kinase inhibitor resistance: A comprehensive review of methods, challenges, and future perspectives

Journal of Intelligent Medicine, EarlyView.
Abstract Kinase inhibitors are essential in targeted cancer therapy, yet resistance often emerges through secondary mutations, activation of compensatory signaling pathways, or drug‐efflux mechanisms. Artificial intelligence (AI) provides a workflow‐based strategy rather than a list of unrelated tools for predicting and addressing kinase‐inhibitor ...
Faris Hassan, Mohanad Ali Deifallah, Alaa Zaghloul, Rania Elgohary   +3 more
wiley   +1 more source

NPM1 and FLT3 mutations in acute myeloid leukemia with normal karyotype: Indian perspective

, 2017
Renu Saxena, Sudha Sazawal, Neha Singh, Sonal Jain, Sunita Chhikara, Rekha Chaubey, Jina Bhattacharyya, KandarpaKr Saikia, Manoranjan Mahapatra   +8 more
openalex   +1 more source

Epigenetic inflammatory memory and periodontal disease: Mechanisms and clinical significance for comorbidities

Journal of Periodontology, EarlyView.
Abstract Historically, immunological memory was considered an exclusive feature of adaptive immunity. However, innate immune cells have recently been shown to record and maintain epigenetically imprinted memory of earlier infectious or inflammatory challenges.
George Hajishengallis
wiley   +1 more source

Management of chronic myeloid leukemia in 2025. [PDF]

Cancer
Kantarjian H, Breccia M, Haddad FG, Hehlmann R, Issa GC, Malhotra H, Nicolini FE, Sasaki K, Stenke L, Jabbour E.   +9 more
europepmc   +1 more source

Improved survival after acute graft-versus-host disease diagnosis in the modern era [PDF]

, 2017
et al.,, Hayashi, Robert J, Vig, Ravi
core   +1 more source